DoW Toxic Exposures Clinical Trial Award
Funding Information
Description
Distinctive Features: To encourage applications that include meaningful and productive collaborations, the FY26 TERP CTA includes a Partnering Principal Investigator Option (PPIO). One Principal Investigator (PI) is identified as the initiating PI, and an additional PI may be identified as a Partnering PI. If recommended for funding, each PI will be named on separate awards. The intent is to support interdisciplinary partnerships, such as those between clinicians and research scientists, that will accelerate the movement of promising interventions/knowledge products into clinical applications. Partnering should significantly advance the research beyond what would be possible through independent efforts.
https://cdmrp.health.mil/pubs/press/2026/terppreann
Synopsis
Summary: The fiscal year 2026 (FY26) Toxic Exposures Research Program (TERP) Clinical Trial Award (CTA) mechanism supports the advancement, execution, and analysis of clinical trials with the potential to have a significant impact on the prevention, treatment, or management of symptoms, diseases or conditions associated with or resulting from military-related toxic exposures. Proposed projects may range from small proof-of-concept clinical trials (e.g., pilot, first-in-human, phase 0) designed to demonstrate the feasibility or inform the design of more advanced trials, through large-scale trials (including pragmatic clinical trials) to determine efficacy in relevant patient populations.
Distinctive Features: To encourage applications that include meaningful and productive collaborations, the FY26 TERP CTA includes a Partnering Principal Investigator Option (PPIO). One Principal Investigator (PI) is identified as the initiating PI, and an additional PI may be identified as a Partnering PI. If recommended for funding, each PI will be named on separate awards. The intent is to support interdisciplinary partnerships, such as those between clinicians and research scientists, that will accelerate the movement of promising interventions/knowledge products into clinical applications. Partnering should significantly advance the research beyond what would be possible through independent efforts.
Eligibility
Funding Activity Categories
CFDA Numbers
- 12.420 - Military Medical Research and Development
Contact Information
Phone: 301-682-5507
Email: help@eBRAP.org
Additional Information
Related Opportunities
Ask Questions
- Can you provide a brief, easy-to-understand summary of this grant opportunity?
- What types of projects or activities would be a good fit for this grant?
- What are the key eligibility requirements and who is most likely to qualify for this grant?
- What are the most important deadlines and timeline considerations for this grant?
- What are the typical costs and budget considerations for projects funded by this grant?
- What are common challenges or pitfalls to avoid when applying for this grant?
- How competitive is this grant and what can improve my chances of success?
- Ask any question...